• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Baxter touts data supporting use of machine learning for infusion pump programming

December 8, 2021 By Sean Whooley

BaxterBaxter (NYSE:BAX) announced today that data shows the potential for machine learning supporting decision-making with infusion pump programming.

Deerfield, Illinois-based Baxter presented the data from a retrospective study — part of a collaboration with MedAware aimed to develop next-generation dose error reduction software — at the American Society of Health-System Pharmacists (ASHP) 2021 Midyear Clinical Meeting.

According to a news release, the study shows that machine learning and its algorithms for finding patterns in large amounts of data could improve the process during programming of smart infusion pumps, which use dose error reduction systems (DERS) to help prevent medication errors by checking programmed doses against preset limits specific to a drug.

Baxter said that developing meaningful DERS limits across all drugs and care areas and deploying changes through thousands of pumps within a hospital is challenging and requires detailed analysis and significant resources. The study sought to examine whether machine learning and artificial intelligence (AI) could inform adjustments to DERS limits using MedAware’s machine learning technology.

The study analyzed more than 3.8 million infusions performed on 20,542 Baxter infusion pumps over a 10-month period, with algorithms set to identify “outliers” that included infusions deviating from commonly programmed doses/rates for specific drugs, uncommon drug concentrations and patient weight entries outside of common weight ranges.

Baxter’s analysis found that 44,819 pump programming entries were outliers and 23% of those triggered DERS soft limits, while 52% triggered DERS hard limits. Approximately 25% of the outliers were identified through MedAware’s technology but did not trigger DERS because the programming parameters were within DERS soft limits.

With the results confirming the challenges associated with maintaining meaningful DERS limits, study investigators concluded that machine learning could help inform future collaboration with hospitals around the development of more clinically relevant DERS limits, potentially supporting increased infusion safety and reducing unnecessary alerts.

“This study shows promise around the potential to enhance patient safety by using machine learning platforms to build and maintain smart infusion drug libraries that dynamically review infusions and signal possible infusion errors,” VP of Medical Affairs for Baxter’s Medication Delivery Business Dr. Douglas M. Hansell said in the release. “Baxter is eager to further explore the use of machine learning and other digital health platforms to generate real-time insights that support individualized clinical decisions.”

Filed Under: Auto-injectors, Big Data, Clinical Trials, Drug-Device Combinations, Featured, Technology Tagged With: Baxter, infusion pump, machine learning algorithms, MedAware

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS